Connection

Robert Harrington to Fibrinolytic Agents

This is a "connection" page, showing publications Robert Harrington has written about Fibrinolytic Agents.
Connection Strength

5.460
  1. Diagnosis and Treatment of Acute Coronary Syndromes: A Review. JAMA. 2022 Feb 15; 327(7):662-675.
    View in: PubMed
    Score: 0.609
  2. Antithrombotic Therapy after Acute Coronary Syndromes. Reply. N Engl J Med. 2021 05 13; 384(19):1873-1874.
    View in: PubMed
    Score: 0.577
  3. Management of Antithrombotic Therapy after Acute Coronary Syndromes. N Engl J Med. 2021 Feb 04; 384(5):452-460.
    View in: PubMed
    Score: 0.567
  4. Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosis. Clin Cardiol. 2014 Jun; 37(6):337-42.
    View in: PubMed
    Score: 0.350
  5. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):670S-707S.
    View in: PubMed
    Score: 0.235
  6. Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):708S-775S.
    View in: PubMed
    Score: 0.235
  7. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):776S-814S.
    View in: PubMed
    Score: 0.235
  8. Advances in antithrombotic therapy in acute myocardial infarction: the ExTRACT-TIMI 25 and OASIS-6 Trials. Curr Cardiol Rep. 2006 Jul; 8(4):279-81.
    View in: PubMed
    Score: 0.206
  9. Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction. Am Heart J. 2006 Feb; 151(2):316-22.
    View in: PubMed
    Score: 0.200
  10. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol. 2006 Feb 21; 47(4):809-16.
    View in: PubMed
    Score: 0.200
  11. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005 Nov 01; 96(9):1200-6.
    View in: PubMed
    Score: 0.195
  12. Interventional cardiovascular pharmacotherapy: current issues. Am J Cardiovasc Drugs. 2005; 5(2):93-102.
    View in: PubMed
    Score: 0.186
  13. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):513S-548S.
    View in: PubMed
    Score: 0.181
  14. Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes. Am J Med. 2004 Jan 15; 116(2):119-29.
    View in: PubMed
    Score: 0.174
  15. Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease. Circulation. 2019 09 24; 140(13):1115-1124.
    View in: PubMed
    Score: 0.129
  16. Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2019 08; 12(8):e007604.
    View in: PubMed
    Score: 0.128
  17. Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial). Circulation. 2018 01 02; 137(1):91-94.
    View in: PubMed
    Score: 0.114
  18. Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients: An Unmet Need. J Cardiovasc Pharmacol Ther. 2016 05; 21(3):227-32.
    View in: PubMed
    Score: 0.097
  19. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Thromb Haemost. 2010 Nov; 104(5):976-83.
    View in: PubMed
    Score: 0.069
  20. Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: a proposal from the academic bleeding consensus (ABC) multidisciplinary working group. Am Heart J. 2009 Dec; 158(6):881-886.e1.
    View in: PubMed
    Score: 0.065
  21. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial. JACC Cardiovasc Interv. 2009 Nov; 2(11):1083-91.
    View in: PubMed
    Score: 0.065
  22. Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). Am J Cardiol. 2008 Nov 15; 102(10):1285-90.
    View in: PubMed
    Score: 0.060
  23. Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2008 Mar 11; 51(10):991-6.
    View in: PubMed
    Score: 0.058
  24. Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2005 Jan 18; 45(2):321-3.
    View in: PubMed
    Score: 0.047
  25. Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):549S-575S.
    View in: PubMed
    Score: 0.045
  26. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):576S-599S.
    View in: PubMed
    Score: 0.045
  27. Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy. Circulation. 2004 Aug 10; 110(6):679-84.
    View in: PubMed
    Score: 0.045
  28. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004 Jul 07; 292(1):89-96.
    View in: PubMed
    Score: 0.045
  29. Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. Am J Cardiol. 2004 Jun 01; 93(11):1362-7, A5-6.
    View in: PubMed
    Score: 0.045
  30. Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004 Feb 18; 43(4):549-56.
    View in: PubMed
    Score: 0.044
  31. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. J Am Coll Cardiol. 2003 Apr 16; 41(8):1251-60.
    View in: PubMed
    Score: 0.041
  32. Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes. J Am Heart Assoc. 2015 Jun 18; 4(6):e001512.
    View in: PubMed
    Score: 0.024
  33. Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. Am J Med. 2010 Feb; 123(2):134-40.
    View in: PubMed
    Score: 0.017
  34. Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY. Int J Cardiol. 2010 Sep 24; 144(1):36-41.
    View in: PubMed
    Score: 0.016
  35. Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes. Am Heart J. 2008 Feb; 155(2):369-74.
    View in: PubMed
    Score: 0.014
  36. Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Circulation. 2007 Dec 04; 116(23):2669-77.
    View in: PubMed
    Score: 0.014
  37. Impact of initial heart rate and systolic blood pressure on relation of age and mortality among fibrinolytic-treated patients with acute ST-elevation myocardial infarction presenting with cardiogenic shock. Am J Cardiol. 2007 Mar 15; 99(6):793-6.
    View in: PubMed
    Score: 0.013
  38. Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal. Catheter Cardiovasc Interv. 2007 Jan; 69(1):73-83.
    View in: PubMed
    Score: 0.013
  39. Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes. Eur Heart J. 2006 Mar; 27(5):527-33.
    View in: PubMed
    Score: 0.012
  40. Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. Am J Cardiol. 2005 Feb 01; 95(3):383-6.
    View in: PubMed
    Score: 0.012
  41. Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. J Am Coll Cardiol. 2004 Apr 07; 43(7):1170-6.
    View in: PubMed
    Score: 0.011
  42. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J. 2003 Oct; 146(4):628-34.
    View in: PubMed
    Score: 0.011
  43. Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. Am Heart J. 2003 Jan; 145(1):73-9.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.